Paediatric community-acquired pneumonia: Current concept in pharmacological control

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 5, 2003, Pages 761-777

  Principi, Nicola ^a   Esposito, Susanna ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

lactams; Antibiotic therapy; Children; Community acquired pneumonia; Haemophilus influenza type b conjugate vaccine; Heptavalent pneumococcal conjugate vaccine; Macrolides

Indexed keywords

AMINOGLYCOSIDE; AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFUROXIME; CEPHALOSPORIN; CHLORAMPHENICOL; CLARITHROMYCIN; CLAVULANIC ACID; COTRIMOXAZOLE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; ERYTHROMYCIN; GENTAMICIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; INFLUENZA VACCINE; MACROLIDE; OXACILLIN; PENICILLIN G; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; SULFONAMIDE; TETRACYCLINE; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ACTIVE IMMUNIZATION; ADOLESCENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; CHILD; CHILDHOOD DISEASE; COMMUNICABLE DISEASE; CONJUGATE; DRUG CLASSIFICATION; DRUG RESISTANCE; DRUG TISSUE LEVEL; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; PATHOGENICITY; PENICILLIN RESISTANCE; PRACTICE GUIDELINE; RECURRENT INFECTION; REVIEW; SUPERINFECTION; VIRUS PNEUMONIA;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; EXPERT TESTIMONY; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; PNEUMONIA; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 0038811604     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.5.761     Document Type: Review

References (118)

1. MCINTOSH K: Community-acquired pneumonia in children. N. Engl. J. Med. (2002) 346(6):429-437.
2. SELWYN BJ: The epidemiology of acute respiratory tract infection in young children: comparison of findings from several developing countries. Rev. Infect. Dis. (1990) 12(Suppl. 8):S870-S888.
3. BAQUI AH, BLACK RE, ARIFEEN SE, HILL K, MITRA SN, AL SABIR A: Causes of childhood deaths in Bangladesh: results of a nationwide verbal autopsy study. Bull. World Health Organ. (1998) 76(2):161-171.
4. BROWN PD, LERNER SA. Community-acquired pneumonia. Lancet (1998) 352(9136):1295-1302.
5. MARRIE TJ: Community-acquired pneumonia. Clin. Infect. Dis. (1994) 18(4):501-515.
6. MULHOLLAND K: Magnitude of the problem of childhood pneumonia. Lancet (1999) 354(9178):590-592.
7. BTS guidelines for the management of community acquired pneumonia in childhood. British thoracic society standards of care committee. Thorax (2002) 57(Suppl. 1):i1-i24.
8. MCCRACKEN GH: Etiology and treatment of pneumonia. Pediatr. Infect. Dis. J. (2000) 19(4):373-377.
9. BRADLEY JS: Management of community-acquired pediatric pneumonia in an era of increasing antibiotic resistance and conjugate vaccines. Pediatr. Infect. Dis. J. (2002) 21(6):592-598.
10. ESPOSITO S, PRINCIPI N: Emerging resistance to antibiotics against respiratory bacteria: impact on therapy of community-acquired pneumonia in children. Drug. Res. Up. (2002) 5(2):73-87.
11. JOKINEN C, HEISKANEN L, JUVONEN H et al.: Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am. J. Epidemiol. (1993) 137(9):977-988.
12. KORPPI M, HEISKANEN-KOSMA T, JALONEN E et al.: Aetiology of community-acquired pneumonia in children treated in hospital. Eur. J. Pediatr. (1993) 152(1):24-30.
13. MURPHY TF, HENDERSON FW, CLYDE WA Jr et al.: Pneumonia: an 11-year study in a pediatric practice. Am. J. Epidemiol. (1981) 113(1):12-21.
14. ZANGWILL KM, VADHEIM CM, VANNIER AM et al.: Epidemiology of invasive pneumococcal disease in southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. J. Infect. Dis. (1996) 174(4):752-759.
15. AMERICAN ACADEMY OF PEDIATRICS: Tobacco's toll: implications for the pediatrician. Pediatrics (2001) 107(4):794-798.
16. GERGEN PJ, FOWLER JA, MAURER KR, DAVIS WW, OVERPECK MD: The burden of environmental tobacco smoke exposure on the respiratory health of children 2 months through 5 years of age in the United States: third national health and nutrition examination survey, 1988 to 1994. Pediatrics (1998) 101(2):E8.
17. LANARI M, GIOVANNINI M, GIUFFRÉ L et al.: Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. Pediatr. Pulmonol. (2002) 33(6):458-465.
18. VUORI-HOLOPAINEN E, PELTOLA H: Reappraisal of lung tap: review of an old method for better etiologic diagnosis of childhood pneumonia. Clin. Infect. Dis. (2001) 32(5):715-726.
19. JUVEN T, MERTSOLA J, WARIS M et al.: Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr. Infect. Dis. J. (2000) 19(4):293-298.
20. HEISKANEN-KOSMA T, KORPPI M, JOKINEN C et al.: Etiology of childhood pneumonia: serologic results of a prospective, population-based study. Pediatr. Infect. Dis. J. (1998) 17(11):986-991.
21. WUBBEL L, MUNIZ L, AHMED A et al.: Etiology and treatment of community-acquired pneumonia in children. Pediatr. Infect. Dis. J. (1999) 18(2):865-871.
22. JOKINEN C, HEISKANEN L, JUVONEN H et al.: Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am. J. Epidemiol. (1993) 137(9):977-988.
23. STAGNO S, BRASFIELD DM, BROWN MB et al.: Infant pneumonitis associated with cytomegalovirus, Chlamydia, Pneumocystis, and Ureaplasma: a prospective study. Pediatrics (1981) 68(3):322-329.
24. TSAI HP, KUO PH, LIU CC, WANG JR: Respiratory viral infections among pediatric inpatients and outpatients in Taiwan from 1997 to 1999. J. Clin. Microbiol. (2001) 39(1):111-118.
25. ESPOSITO S, BOSIS S, CAVAGNA R et al.: Characteristics of Streptococcus pneumoniae and atypical bacteria infections in children 2 to 5 years of age with community-acquired pneumonia. Clin. Infect. Dis. (2002) 35(12):1345-1352.
26. PRINCIPI N, ESPOSITO S, BLASI F, ALLEGRA L, THE MOWGLI STUDY GROUP: Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections. Clin. Infect. Dis. (2001) 32(9):1281-1289.
27. HARRIS JS, KOLOKATHIS A, CAMPBELL M et al.: Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr. Infect. Dis. J. (1998) 17(10):865-871.
28. BLOCK S, HEDRICK J, HAMMERSCHLAG et al.: Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin versus erythromycin ethylsuccinate. Pediatr. Infect. Dis. J. (1995) 14(6):471-477.
29. ESPOSITO S, BLASI F, BELLINI F, ALLEGRA L, PRINCIPI N, THE MOWGLI STUDY GROUP: Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with pneumonia. Eur. Resp. J. (2001) 17(2):241-245.
30. PRINCIPI N, ESPOSITO S: Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory tract infections. Lancet Infect. Dis. (2001) 1(5):334-344.
31. TOIKKA O, JUVÉN T, VIRKKI R, LEINONEN M, MERTSOLA J, RUUSKANEN O: Streptococcus pneumoniae anti Mycoplasma pneumoniae coinfection in community acquired pneumonia. Arch. Dis. Child. (2000) 83(5):413-434.
32. RAMSEY BW, MARCUSE EK, FOY HM et al.: Use of bacterial antigen detection in the diagnosis of pediatric lower respiratory tract infections. Pediatrics (1986) 78(1):1-9.
33. TURNER RB, LANDE AE, CHASE P, HILTON N, WEINBERG D: Pneumonia in pediatric outpatients: cause and clinical manifestations. J. Pediatr. (1987) 111(2):194-200.
34. FORGIE IM, O'NEILL KP, LLOYD-EVANS N et al.: Etiology of acute lower respiratory tract infections in Gambian children. I. Acute lower respiratory tract infections in infants presenting at the hospital. Pediatr. Infect. Dis. J. (1991) 10(1):33-41.
35. COURTOY I, LANDE AE, TURNER RB: Accuracy of radiographic differentiation of bacterial from nonbacterial pneumonia. Clin. Pediatr. (1989) 28(6):261-264.
36. KORPPI M, KIEKARA O, HEISKANEN-KOSMA T, SOIMAKALLIO S: Comparison of radiological findings and microbial aetiology of childhood pneumonia. Acta Paediatr. (1993) 82(4):360-363.
37. NOHYNEK H, VALKEILA E, LEINONEN M, ESKOLA J: Erythrocyte sedimentation rate, white blood cell count and serum C-reactive protein in assessing etiologic diagnosis of acute lower respiratory tract infections in children. Pediatr. Infect. Dis. J. (1995) 14(6):484-490.
38. KORPPI M, HEISKANEN-KOSMA T, LEINONEN M: White blood cells, C-reactive protein and erythrocyte sedimentation rate in pneumococcal pneumonia in children. Eur. Resp. J. (1997) 10(5):1125-1129.
39. KORPPI M, REMES S: Serum procalcitonin in pneumococcal pneumonia in children. Eur. Resp. J. (2001) 17(4):623-627.
40. MOULIN F, RAYMOND J, LORROT M et al.: Procalcitonin in children admitted to hospital with community-acquired pneumonia. Arch. Dis. Child. (2001) 84(4):332-336.
41. KORPPI M, REMES S, HEISKANEN-KOSMA T: Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings. Pediatr. Pulmonol. (2003) 35(1):56-61.
42. VIRKKI R, JUVEN T, RIKALAINEN H, SVEDSTROM E, MERTSOLA J, RUUSKANEN O: Differentiation of bacterial and vital pneumonia in children. Thorax (2002) 57(5):438-441.
43. VUORI-HOLOPAINEN E, SALO E, SAXEN H et al.: Etiological diagnosis of childhood pneumonia by use of transthoracic needle aspiration and modern microbiological methods. Clin. Infect. Dis. (2002) 34(5):583-590.
44. MICHELOW IC, LOZANO J, OLSEN K et al.: Diagnosis of Streptococcus pneumoniae lower respiratory infection in hospitalized children by culture, polymerase chain reaction, serological testing, and urinary antigen detection. Clin. Infect. Dis. (2002) 34(1):e1-e11.
45. KORPPI M, HEISKANEN-KOSMA T, LEINONEN M et al.: Antigen and antibody assays in the aetiological diagnosis of respiratory infection in children. Acta Pediatr. (1993) 82(2):137-141.
46. DOWELL SF, GARMAN RL, LIU G, LEVINE OS, YANG YH: Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients. Clin. Infect. Dis. (2001) 32(5):824-825.
47. NEUMAN MI, HARPER MB: Rapid antigen assay for the diagnosis of pneumococcal bacteremia in children: a preliminary study. Ann. Emerg. Med. (2002) 40(4):399-404.
48. GUTIERREZ F, MASIA M, RODRIGUEZ JC et al.: Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin. Infect. Dis. (2003) 36(3):286-292.
49. JADAVJI T, LAW B, LEBEL MH, KENNEDY WA, GOLD R, WANG EE: A practical guide for the diagnosis and treatment of pediatric pneumonia. Can. Med. Ass. J. (1997) 156(5):S703-S711.
50. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br. J. Hosp. Med. (1993) 49(9):346-350.
51. NIEDERMAN MS, BASS JB Jr, CAMPBELL GD et al.: Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am. Rev. Respir. Dis. (1993) 148(5):1418-1426.
52. BARTLETT JG, DOWELL SF, MANDELL LA, FILE TM Jr, MUSHER DM, FINE MJ: Practice guidelines for the management of community-acquired pneumonia in adults. Clin. Infect. Dis. (2000) 31(2):347-382.
53. RUUSKANEN O, MERTSOLA J: Childhood community-acquired pneumonia. Semin. Respir. Infect. (1999) 14(2):163-172.
54. FINCH R: Community-acquired pneumonia: the evolving challenge. Clin. Microbiol. Infect. (2001) 7(Suppl. 3):30-38.
55. DOERN GV, BRUGGEMANN AB, HUYNH H, WINGERT E: Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997 - 1998. Emerg. Infect. Dis. (1999) 5(6):757-765.
56. DOERN GV, PFALLER MA, KUGLER K, FREEMAN J, JONES RN: Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. Clin. Infect. Dis. (1998) 27(4):764-770.
57. FELMINGHAM D, GRUNEBERG RN: The Alexander Project 1996 - 1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob. Chemother. (2000) 45(2):191-203.
58. SCHITO GC, DEBBIA EA, MARCHESE A. The evolving threat of antibiotic resistance in Europe: new data ftom the Alexander Project. J. Antimicrob. Chemother. (2000) 46(Suppl. T1):3-9.
59. MARCHESE A, MANNELLI S, TONOLI E, GORLERO F, TONI M, SCHITO GC: Prevalence of antimicrobial resistance in Streptococcus pneumoniae circulating in Italy: results of the Italian Epidemiological Observatory Survey (1997 - 1999). Microb. Drug Resist. (2001) 7(3):277-287.
60. BAUER T, EWIG S, MARCOS MA, SCHULTZE-WERNINGHAUS G, TORRES A. Streptococcus pneumoniae in community-acquired pneumonia. How important is drug resistance? Med. Clin. North Am. (2001) 85(6):1367-1379.
61. KLUGMAN KP: Epidemiology, control and treatment of multiresistant pneumococci. Drugs (1996) 52(Suppl. 2):42-46.
62. HEFFELFINGER JD, DOWELL SF. JORGENSEN JH et al.: Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch. Intern. Med. (2000) 160(10):1399-1408.
63. TAN TQ, MASON EO JR, BARSON WJ et al.: Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillin-nonsusceptible Streptococcus; pneumoniae. Pediatrics (1998) 102(6):1369-1375.
64. FRIEDLAND IR. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr. Infect. Dis. J. (1995) 14(10):885-890.
65. DEEKS SL, PALACIO R, RUVINSKY R et al.: Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. Pediatrics (1999) 103(2):409-413.
66. Therapy for children with invasive pneumococcal infections. American academy of pediatrics committee on infectious diseases. Pediatrics (1997) 99(2):289-299.
67. MLYNARCZYK G, MLYNARCZYK A, JELJASZEWICZ J: Epidemiological aspects of antibiotic resistance in respiratory pathogens. Intern. J. Antimicrob. Agents (2001) 18(6):497-502.
68. GARAU J: The clinical impact of macrolide resistance in pneumococcal respiratory infections. Intern. J. Antimicrob. Agents (2001) 18(Suppl. 1):S33-S38.
69. JACOBS MR, BAJAKSOUZIAN S, ZILLES A, LIN G, PANKUCH GA, APPELBAUM PC: Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US Surveillance sudy. Antimicrob. Agents Chemother. (1999) 43(8):1901-1908.
70. THORNSBERRY C, SAHM DF: Antimicrobial resistance in respiratory tract pathogens: results of an international surveillance study. J. Chemother. (2000) 46(Suppl. 1):15-23.
71. HSUEH PR, TENG LJ, LEE LN, YANG PC, HO SW, LUH KT: Extremely high incidence of macrolide and trimethoprim-sulfamethoxazole resistance among clinical isolates of Streptococcus pneumoniae in Taiwan. J. Clin. Microbiol. (1999) 37(4):897-901.
72. MARCHESE A, TONOLI E, DEBBIA EA, SCHITO GC: Macrolide resistance mechanisms and expression of phenotypes among Streptococcus pneumoniae circulating in Italy. J. Antimicrob. Chemother. (1999) 44:461-464.
73. UBUKATA K, SHIBASAKI Y, YAMAMOTO K et al.: Association of aminoacid substitutions in penicillin-binding protein 3 with β-lactam resistance in β-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob. Agents Chemother. (2001) 45(6):1693-1699.
74. DOERN GV, BRUEGGEMANN AB, PIERCE G, HOLLEY HP, RAUCH A: Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of β-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob. Agents Chemother. (1997) 41(2):292-297.
75. SANCHEZ L, LERANOZ S, PUIG M, LOREN JG, NIKAIDO H, VINAS M: Molecular basis of antimicrobial resistance in non-typable Haemophilus influenzae. Microbiologia (1997) 13(3):309-314.
76. SANCHEZ L, PAN W, VINAS M, NIKAIDO H: The acrAB homolog of Haemophilus influenzae codes for a functional multidrug efflux pump. J. Bacteriol. (1997) 179(21):6855-6857.
77. JAIN S: Perinatally acquired Chlamydia trachomatis associated morbidity in young infants. J. Matern. Fetal Med. (1999) 8(3):130-133.
78. LEHMANN D, SANDERS RC, MARJEN B et al.: High rates of Chlamydia trachomatis infections in young Papua New Guinean infants. Pediatr. Infect. Dis. J. (1999) 18(Suppl. 10):S62-S69.
79. VON KONIG CH, HALPERIN S, RIFFELMANN M, GUISO N: Pertussis of adults and infants. Lancet Infect. Dis. (2002) 2(12):744-750.
80. PRINCIPI N, ESPOSITO S: Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Drug Saf. (1999) 20(1):25-41.
81. JACKSON MA, BURRY VF, OLSON LC, DUTHIE SE, KEARNS GL: Breakthrough sepsis in macrolide-resistant pneumococcal infection. Pediatr. Infect. Dis. J. (1996) 15(11):1049-1051.
82. GARAU J, LONKS JR, GOMEZ L, XERCAVINS M, MEDEIROS AA: Failure of macrolide therapy in patients with bacteremia due to macrolide resistant Streptococcus pneumoniae. Fifth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, Seville, Spain, (2000) (Abstract 7.09).
83. HYDE TB, GAY K, STEPHENS DS et al.: Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA (2001) 286(15):1857-1862.
84. FILE TJ JR: Community-acquired pneumonia: new guidelines for management. Curr. Opin. Infect. Dis. (2001) 14(2):161-164.
85. EASTON J, NOBLE S, PERRY CM: Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media. Drugs (2003) 63(3):311-340.
86. HOBERMAN A, PARADISE JL, BURCH DJ et al.: Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for treatment of acute otitis media in children. Pediatr. Infect. Dis. J. (1997) 16(5):463-470.
87. WOODNUTT G, BERRY V: Efficacy of high-dose amoxicillin/clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. (1999) 43(1):35-40.
88. PALADINO JA, GUDGEL LD, FORREST A, NIEDERMAN MS: Cost-effectiveness of IV-to-oral switch therapy: azithromycin versus cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Chest (2002) 122(4):1271-1279.
89. PRINCIPI N, ESPOSITO S: Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Drug Safety (1999) 20(1):25-41.
90. OWAYED AF, CAMPBELL DM, WANG EEL: Underlying causes of recurrent pneumonia in children. Arch. Pediatr. Adolesc. Med. (2000) 154(2):190-194.
91. LODHA R, PURANIK M, NATCHU UC, KABRA SK: Recurrent pneumonia in children: clinical profile and underlying causes. Acta. Paediatr. (2002) 91(11):1170-1173.
92. VAUGHAN D, KATKIN JP: Chronic and recurrent pneumonias in children. Semin. Respir. Infect. (2002) 17(1):72-84.
93. HEATH PT, MCVERNON J: The UK Hib vaccine experience. Arch. Dis. Child. (2002) 86(6):396-399.
94. Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children - United States, 1998 - 2000. Centers for disease control and prevention. JAMA (2002) 287(17):2206-2207.
95. OBARO SK, ENWERE GC, DELORIA M et al.: Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine. Pediatr. Infect. Dis. J. (2002) 21(10):940-947.
96. JUVEN T, MERTSOLA J, TOIKKA P, VIRKKI R, LEINONEN M, RUUSKANEN O: Clinical profile of serologically diagnosed pneumococcal pneumonia. Pediatr. Infect. Dis. J. (2001) 20(11):1028-1033.
97. TAN TQ, MASON EO, WALD ER et al.: Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Pediatrics (2002) 110(1):1-6.
98. ESPOSITO S, MADORE DV, GIRONI S et al.: Theoretic coverage of heptavalent pneumococcal conjugate vaccine in the prevention of community-acquired pneumonia in children in Italy. Vaccine (2003) (In Press).
99. BLACK SB, SHINEFIELD HR, LING S et al.: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. (2002) 21(9):810-815.
100. RAY GT, BUTLER JC, BLACK SB, SHINEFIELD HR, FIREMAN BH, LIEU TA: Observed costs and health care use of children in a randomized controlled trial of pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. (2002) 21(5):361-365.
101. FEIKIN DR, KLUGMAN KP: Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin. Infect. Dis. (2002) 35(5):547-555.
102. DARKES MJ, PLOSKER GL: Pneumococcal conjugate vaccine (Prevenar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection. Paediatr. Drugs (2002) 4(9):609-630.
103. WHITNEY CG, PICKERING LK: The potential of pneumococcal conjugate vaccines for children. Pediatr. Infect. Dis. J. (2002) 21(10):961-970.
104. SCHAFFER SJ, SZILAGYI PG, SHONE LP et al.: Physician perspectives regarding pneumococcal conjugate vaccine. Pediatrics (2002) 110(6):e68.
105. NEUZIL KM, MELLEN BG, WRIGHT PF, MITCHEL EF, GRIFFIN MR: The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N. Engl. J. Med. (2000) 342(4):225-231.
106. IZURIETA HS, THOMPSON WW, KRAMARZ P et al.: Influenza and the rates of hospitalization for respiratory disease among infants and young children. N. Engl. J. Med. (2000) 342(4):232-239.
107. NEUZIL EM, WRIGHT PF, MITCHEL EF, GRIFFIN MR: The burden of influenza illness in children with asthma and other chronic medical conditions. J. Pediatr. (2000) 137(6):856-864.
108. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR (2002) 51(RR03):1-31.
109. CHIU SS, LAU YL, CHAN KH, WONG WHS, PEIRIS JSM: Influenza-related hospitalizations among children in Hong Kong. N. Engl. J. Med. (2002) 347(26):2097-2103.
110. O'BRIEN KL, WALTERS MI, SELLMAN J et al.: Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin. Infect. Dis. (2000) 30(5):784-789.
111. HURWITZ ES, HABER M, CHANG A et al.: Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA (2000) 284(13):1677-1682.
112. REICHERT TA, SUGAYA N, FEDSON DS, GLEZEN WP, SIMONSEN L, TASHIRO M: The Japanese experience with vaccinating school children against influenza. N. Engl. J. Med. (2001) 344(12):889-896.
113. NEUZIL KM, HOHLBEIN C, ZHU Y: Illness among schoolchildren during influenza season. Effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch. Pediatr. Adolesc. Med. (2002) 156(10):986-991.
114. ESPOSITO S, FALDELLA G, GIAMMANCO A et al.: Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term infants. Vaccine (2002) 20(23-24): 2928-2932.
115. ESPOSITO S, AGLIARDI T, GIAMMANCO A et al.: Long-term pertussis-specific immunity after a primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in comparison with natural infection. Infect. Immun. (2001) 69(7):4516-4520.
116. MARDH PA. Influence of infection with Chlamydia trachomatis on pregnancy outcome, infant health and life-long sequelae in infected offspring. Best Pract. Res. Clin. Obstet. Gynaecol (2002) 16(6):847-864.
117. RASTOGI S, DAS B, SALHAN S, MITTAL A: Effect of treatment for Chlamydia trachomatis during pregnancy. Int. J. Gynaecol. Obstet. (2003) 80(2):129-137.
118. PIMENTA JM, CATCHPOLE M, ROGERS PA et al.: Opportunistic screening for genital chlamydial infection. II: prevalence among healthcare attenders, outcome, and evaluation of positive cases, Sex. Transm. Infect. (2003) 79(1):22-27.